Unknown PHASE2 INTERVENTIONAL 1-arm NCT01931488

124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.

The Feasibility of Novel 124I-MIBG Tracer in Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. Comparison With 123I-MIBG.

Sponsor: Tel-Aviv Sourasky Medical Center

Conditions Neuroendocrine Tumors Parkinson Disease

Interventions MIBG label with I123 or I124 SPECT imaging

Updated 6 times since 2017 Last updated: Aug 28, 2013 Started: Aug 31, 2013 Primary completion: Jan 31, 2015 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Neuroendocrine Tumors and Parkinson Disease, this trial is ongoing. The trial is conducted by Tel-Aviv Sourasky Medical Center and has accumulated 6 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tel-Aviv Sourasky Medical Center

Data source: Tel-Aviv Sourasky Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tel Aviv, Israel